Division of Pediatric Critical Care Medicine, Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI.
Department of Pediatrics, University of California, Los Angeles, CA.
Pediatr Crit Care Med. 2018 Oct;19(10):930-938. doi: 10.1097/PCC.0000000000001680.
To test whether plasma interleukin-1 receptor antagonist or variants within the gene encoding for interleukin-1ra (IL1RN), or proteins involved in regulating interleukin-1β levels or interleukin-1β response, are associated with pediatric acute respiratory distress syndrome or outcomes in mechanically ventilated children with parenchymal lung disease.
Prospective cohort study.
Twenty-two PICUs participating in the multisite clinical trial, Randomized Evaluation of Sedation Titration for Respiratory Failure (U01 HL086622).
Children 2 weeks to 17 years old treated with invasive mechanical ventilation for acute airways and/or parenchymal lung disease.
Three-hundred seventy-eight of 549 patients had pediatric acute respiratory distress syndrome; DNA and plasma were obtained from 523 of 549 and 480 of 549 patients, respectively. Plasma interleukin-1ra was highest on the day of intubation (day 0) and decreased over the subsequent 3 days (p < 0.0001). Interleukin-1ra level was higher in patients with pediatric acute respiratory distress syndrome than those without pediatric acute respiratory distress syndrome (p < 0.0001). Multivariable regression analysis of data across all days demonstrated a significant association of interleukin-1ra (odds ratio, 1.30; 95% CI, 1.10-1.52; p = 0.002) and day (p < 0.05) with pediatric acute respiratory distress syndrome, independent of age and Pediatric Risk of Mortality-III score. Analysis on individual days indicated that plasma interleukin-1ra levels were associated with pediatric acute respiratory distress syndrome on days 0 and 2, independent of age and Pediatric Risk of Mortality-III score (p = 0.04 and 0.003, respectively), however did not quite reach significance on days 1 and 3 (p = 0.06 and 0.07, respectively). Interleukin-1ra was independently associated with mortality on day 1 (p = 0.02). Interleukin-1ra also correlated with length of mechanical ventilation, measures of oxygenation, and PICU length of stay. No genetic variants were associated with pediatric acute respiratory distress syndrome.
Plasma interleukin-1ra is associated with pediatric acute respiratory distress syndrome, PICU length of stay, length of mechanical ventilation, and mortality in children with acute respiratory failure requiring mechanical ventilation.
检测白细胞介素-1 受体拮抗剂(IL-1Ra)或其基因(IL1RN)中的变异体,或参与调节白细胞介素-1β水平或白细胞介素-1β反应的蛋白质,是否与儿科急性呼吸窘迫综合征(pediatric acute respiratory distress syndrome,pARDS)或机械通气治疗的肺实质疾病患儿的结局有关。
前瞻性队列研究。
22 个参与多中心临床试验的儿科重症监护病房(pediatric intensive care units,PICUs),随机评价镇静滴定治疗呼吸衰竭(U01 HL086622)。
2 周至 17 岁、因急性气道和/或肺实质疾病行有创机械通气治疗的患儿。
549 例患儿中 378 例患有 pARDS;549 例患儿中分别有 523 例和 480 例获得了 DNA 和血浆;白细胞介素-1Ra 在插管当天(第 0 天)最高,随后 3 天逐渐下降(p<0.0001)。患有 pARDS 的患儿白细胞介素-1Ra 水平明显高于无 pARDS 患儿(p<0.0001)。对所有天数的数据进行多变量回归分析显示,白细胞介素-1Ra(比值比,1.30;95%可信区间,1.10-1.52;p=0.002)和天数(p<0.05)与 pARDS 独立相关,与年龄和小儿危重病评分-III(pediatric risk of mortality-III,PRISM-III)评分无关。对个别天数的分析表明,白细胞介素-1Ra 水平与第 0 天和第 2 天的 pARDS 独立相关,与年龄和 PRISM-III 评分无关(p=0.04 和 0.003),但在第 1 天和第 3 天无显著相关性(p=0.06 和 0.07)。白细胞介素-1Ra 与第 1 天的死亡率独立相关(p=0.02)。白细胞介素-1Ra 与机械通气时间、氧合指标和 PICULOS 时间也相关。基因变异与 pARDS 无相关性。
在需要机械通气治疗的急性呼吸衰竭患儿中,白细胞介素-1Ra 与 pARDS、PICULOS 时间、机械通气时间和死亡率有关。